Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes

European Journal of Haematology

Volumn 63, Issue 2, 1999, Pages 77-85

  Pagano, Livio ^a,c   Antinori, Andrea ^b   Ammassari, Adriana ^b   Mele, Luca ^a   Nosari, Annamaria ^d   Melillo, Lorella ^e   Martino, Bruno ^f   Sanguinetti, Maurizio ^c,g   Equitani, Francesco ^a   Nobile, Francesco ^f   Carotenuto, Mario ^e   Morra, Enrica ^d   Morace, Giulia ^c,g   Leone, Giuseppe ^a  

^a Istituto di Semeiotica Medica   (Italy)

^b Dipartimento di Malattie Infettive e Tropicali   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^f Grande Ospedale Metropolitano di Reggio Calabria   (Italy)

^g IRCCS L Spallanzaui   (Italy)

Author keywords

Candidemia; Leukemia

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; GLYCOPEPTIDE; ITRACONAZOLE; NYSTATIN;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; CANDIDA; CANDIDIASIS; CASE CONTROL STUDY; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; FEMALE; FUNGEMIA; HEMATOLOGIC DISEASE; HUMAN; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MULTIPLE MYELOMA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL;

EID: 0032772819     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01120.x     Document Type: Article

References (39)

1. 1. JARVIS WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-1530.
2. 2. MARTINO P, GIRMENIA C, MICOZZI A, et al. Fungemia in patients with leukemia. Am J Med Sci 1993;306:225-232.
3. 3. WALSH TS, DE PAUW B, ANAISSIE E, MARTINO P. Recent advances in the epidemiology, prevention and treatment of invasive fungal infections in neutropenic patients. J Med Vet Myc 1994;32:33-51.
4. 4. MEUNTER F, AOUN M, BITAR N. Candidemia in immunocompromised patients. Clin Infect Dis 1992;14(suppl 1):S120-125.
5. 5. HORN R, WONG B, KIEHN TE, ARMSTRONG D. Candidemia in cancer hospital: changing frequency, earlier onset, and result of therapy. Rev Infect Dis 1985;7:646-655.
6. 6. RIBEIRO P, SOUSA AB, NUNES O, AVEIRO F, FERNANDES JP, GOUVEIA J. Candidemia in acute leukaemia patients. Support Care Cancer 1997;5:249-251.
7. 7. GOODRICH JM, REED EC, MORI M, et al. Clinical Features and Analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991;164:731-740.
8. 8. IWAMA A, YOSHIDA M, OBAYASHI T, SAKAMOTO S, MIURA Y. Improved survival from fungemia in patients with hematological malignancies: analysis of risk factors for death and usefulness of early antifungal therapy. Eur J Haematol 1993;51:156-160.
9. 9. RICHET HM, ANDREMONT A, TANCREDE C, PICO JL, JARVIS WR. Risk factors for candidemia infection in patients with acute lymphocytic leukemia. Rev Infect Dis 1997;13:211-215.
10. 10. SCHWARTZ RS, MACKINTOSH FR, SCHRIER SL, GREENSBERG PL. Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia. Cancer 1984;53:411-419.
11. 11. MARTINO P, GIRMENIA C, VENDITTI M, et al. Candida colonization and systemic infection in neutropenic patients. Cancer 1989;64:2030-2034.
12. 12. WEY SB, MORI M, PFALLER MA, WOOLSON RF, WENZEL RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989;149:2349-2353.
13. 13. MARTINO P, GIRMENIA C, MICOZZI A, DE BERNARDIS F, BOCCANERA M, CASSONE A. Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycoses in neutropenic patients. Eur J Clin Microbiol Infect Dis 1994;13:797-804.
14. 14. WENZEL RP. Nosocomial candidemia: Risk factors and attributable mortality. Clin Inf Dis 1995;20:1531-1534.
15. 15. GUIOT HFL, FIBBE WE, VAN'T WOUT JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994;18:525-532.
16. 16. FRASER VJ, JONES M, DUNKEL J, STORFER S, MEDOFF G, DUNAGAN WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-421.
17. 17. NGUYEN MH, PEACOCK JE, MORIS AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996;100:617-623.
18. 18. BLUMBERG EA, REBOLI AC. Failure of systemic empirical treatment with amphotericin B to prevent candidemia in neutropenic patients with cancer. Clin Infect Dis 1996;22:462-466.
19. 19. LECCIONES JA, LEE JW, NAVARRO EE, et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992;14:875-883.
20. 20. ANTTILA VJ, ELONEN E, NORDLING S, SIVONEN A, RUUTU T, RUUTU P. Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. Clin Infect Dis 1997;24:375-380.
21. 21. MARINA NM, FLYNN PM, RIVERA GK, HUGHES WT. Candida tropicalis and Candida albicans fungemia in children with leukemia. Cancer 1991;68:594-599.
22. 22. ABI-SAID D, ANAISSIE E, UZUM O, RAAD I, PINZCOWSKI H, VARTIVARIAN S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24:1122-1128.
23. 23. WINGARD JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995;20:115-125.
24. 24. MCQUILLEN DP, ZINGMAN BS, MEUNIER F, LEVITZ SM. Invasive infection due to Candida krusei: report of ten cases of fungemia that include three cases of endophtalmitis. Clin Infect Dis 1992;14:472-478.
25. 25. KOMSHIAN SV, UWAYDAH AK, SOBEL JD, CRANE LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristic, and evaluation of factors influencing outcome. Rev Infect Dis 1989;11:379-390.
26. 26. DATO VM, DAJANA AS. Candidemia in children with central venous catheters: role of catheter removal and amphotericin B therapy. Pediatr Infect Dis 1990;9:309-314.
27. 27. CURRY CR, QUIE PG. Fungal septicemia in patient receiving parenteral hyperalimentation. N Engl J Med 1971;285:1221-1225.
28. 28. NORWOOD S, RUBY A, CIVETTA J, CORTES V. Catheter-related infections and associated septicemia. Chest 1991;99:968-975.
29. 29. MENICHETTI F, DEL FAVERO A, MARTINO P, et al. GIMEMA Infection Program. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med 1994;120:913-918.
30. 30. MARTIN E, PARRAS P, DEL CARMEN LOZANO M. In vitro susceptibility of 245 yeast isolated to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole. Microbiology 1992;38:335-339.
31. 31. UZUN O, ANAISSIE E. Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. Blood 1995;86:2063-2072.
32. 32. NOSARI A, CANTONI S, MUTI G, CAIROLI D, DE CATALDO F. Itraconazole in leukemic patients with invasive aspergillosis (IA): impact on intensive chemoterapy completion. Eur J Haematol 1994;53:183-185.
33. 33. HARDIN TC, GRAYBILL JR, FETCHICK R, WOESTENBORGHS R, RINALDI MG, KUHN JG. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988;32: 1310-1313.
34. 34. SMITH PD, LAMERSON CL, BANKS SM, et al. Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans. J Infect Dis 1990;161:999-1005.
35. 35. DI MARIO A, SICA S, SALUTARI P, ORTU LA BARBERA E, MARRA R, LEONE G. Granulocyte colony-stimulating factor-primed leukocyte transfusions in Candida tropicalis fungemia in neutropenic patients. Haematologica 1997;82:362-363.
36. 36. NGUYEN MH, PEACOCK JE, TANNER DC, et al. Therapeutic approaches in patients with candidemia. Arch Intern Med 1995;155:2429-2435.
37. 37. REX JH, BENNET JE, SUGAR AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-1330.
38. 38. KAUFFMAN CA. Role of azoles in antifungal therapy. Clin Infect Dis 1996;22(suppl 2):s148-s153.
39. 39. ANAISSIE EJ, VARTIVARIAN SE, ABI-SAID D, et al. Fluconazole versus amphotericin B in the treatment of hematogenus candidiasis: a matched cohort study. Am J Med 1996;101:170-176.